Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
EQ vs ENTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ENTX Captures Overall Composite Edge (47.5 HOLD vs 48.6 HOLD), While EQ Leads 3–1 on Growth & Valuation Pillars
ENTX Overall Winner
6-Pillar Tally: EQ 3 – 1 ENTX (2 Tie)
Matrix Metrics: EQ 4 – 4 ENTX
As of Nov 20, 2026, Entera Bio Ltd. (ENTX) captures the overall head-to-head institutional edge over Equillium, Inc. (EQ) on higher Unified Composite conviction (47.5/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 4–4 (led by Options & Positioning), while EQ wins 3–1 across the 6-pillar growth and valuation breakdown. EQ trades at $1.06 (1.5x Forward P/E, 0.0% operating margin) versus ENTX at $3.31 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While EQ currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-100.0% vs. -52.3% YoY).
- Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.7); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About EQ vs ENTX
EQ
Equillium, Inc. Common Stock
$1.06
-5.36% 1D
Market Cap
$92.2M
TTM Revenue
$4.4M
Forward P/E
1.5x
Beta / 30D Vol
1.54β · 89% Vol
Unified Composite Score
48.6
HOLD
Tech 29.0
Fund 55.0
Flow 63.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
ENTX
Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
$3.31
+0.76% 1D
Market Cap
$571.2M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.92β · 53% Vol
Unified Composite Score
47.5
HOLD
Tech 52.0
Fund 49.0
Flow 72.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (EQ 3 – 1 ENTX)
1. Valuation Multiples
EQ
Forward P/E
1.5x
N/M
Trailing P/E
1.5x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
8.1x
N/M
2. Growth & Scale
EQ
Revenue Growth (YoY)
-52.3%
-100.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$4.4M
N/A
Market Cap
$92.2M
$571.2M
3. Profitability & Quality
Tie
Gross Margin
100.0%
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-59.0%
-20.3%
4. Balance Sheet & Cash Flow
EQ
Cash Generation (TTM)
-$20M
-$16M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$57M Net Cash
$265M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ENTX
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
261.3% (100th %ile)
116.0% (33rd %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: EQ (4) vs ENTX (4)| Institutional Metric | EQ | ENTX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $92.2M | $571.2M | ENTX | |
| Trailing P/E Ratio | 1.5x | N/M | EQ | |
| Forward P/E Ratio | 1.5x | N/M | EQ | |
| Revenue Growth (YoY) | -52.3% | -100.0% | EQ | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -59.0% | -20.3% | ENTX | |
| 52-Week Range Position | 9% ($1–$4) | 73% ($1–$4) | ENTX | |
| Beta / 30D Volatility | 1.54β · 89% Vol | 0.92β · 53% Vol | ENTX | |
| Unified Institutional Score | 48.6 / 100 (HOLD) | 47.5 / 100 (HOLD) | EQ | |
| Trailing 12M Revenue (USD) | $4.4M | N/A | Scale | |
| Gross Profit Margin (TTM) | 100.0% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 8.1x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$20M ($57M Net Cash) | -$16M ($265M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ENTX +25.98 pp
3M Horizon
ENTX +48.46 pp
6M Horizon
ENTX +219.63 pp
1Y Horizon
ENTX +19.77 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EQ Revenue | ENTX Revenue | EQ Op. Margin | ENTX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | N/A | $0M | N/A | -3059.7% | ENTX |
| FY2021 | N/A | $0M | N/A | -2139.6% | ENTX |
| FY2022 | $20M | $0M | -393.9% | -9714.2% | EQ |
| FY2023 | $40M | N/A | -40.2% | N/A | EQ |
| FY2024 | $40M | $0M | -20.1% | -5295.6% | EQ |
| FY2025 | N/A | $0M | N/A | -27450.0% | ENTX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
EQ
UNCLASSIFIED
Current IV
261.3%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ENTX
CONSOLIDATION
Current IV
116.0%
IV Percentile
33rd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
EQ Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ENTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ EQ vs ENTX Key Questions & Quantitative Answers
As of Nov 20, 2026, Entera Bio Ltd. (ENTX) captures the overall head-to-head institutional edge over Equillium, Inc. (EQ) on higher Unified Composite conviction (47.5/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 4–4 (led by Options & Positioning), while EQ wins 3–1 across the 6-pillar growth and valuation breakdown. EQ trades at $1.06 (1.5x Forward P/E, 0.0% operating margin) versus ENTX at $3.31 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EQ currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-100.0% vs. -52.3% YoY). Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.7); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EQ leads the Growth & Scale pillar: EQ posts -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), EQ cumulative revenue shifted +100.0% while ENTX shifted N/A. In operating R&D and SG&A reinvestment, EQ deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.
EQ screens cheaper on headline valuation multiples. EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 8.1x EV/Revenue (unreported FCF margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EQ (-59.0% ROE) versus ENTX (-20.3% ROE) capital efficiency.
In options market volatility and institutional positioning, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.54β · 89% Vol realized risk). By comparison, ENTX carries 116.0% implied volatility (33rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 53% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ENTX vs EQ · Reverse Pair
EQ vs ECOR
· Sector Peer
EQ vs CRVS
· Sector Peer
ENTX vs IMMP
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking